Roger Tung, Concert Pharmaceuticals CEO
One trial down, one to go as Concert Pharmaceuticals tunes up PhIII win for alopecia drug
Just two months ago, Concert Pharmaceuticals offloaded most of its CNS pipeline to tiny Terran Biosciences as a make-or-break data readout was well on its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
